David Ching Siang Huang (David C S Huang, Xin Huang)

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2016-2023
Publications (10 Years): 25

Top Venues

Blood

Cell death and differentiation

Cancer discovery

Nature communications

The Walter & Eliza Hall Institute of Medical Research

This page only lists publications with an associated author ORCID identifier.

Affiliation History

The Walter & Eliza Hall Institute of Medical Research Jan 01 2019

Australia

Laboratory Head :: Blood Cells and Blood Cancer

Publications

Zilu Wang, Matteo Burigotto, Sabrina Ghetti, François Vaillant, Tao Tan, Bianca D Capaldo, Michelle Palmieri, Yumiko Hirokawa, Lin Tai, Daniel S Simpson, Catherine Chang, Allan Shuai Huang, Elizabeth Lieschke, Sarah T Diepstraten, Deeksha Kaloni, Chris Riffkin, David Ching Siang Huang, Connie Li Wai Suen, Alexandra L Garnham, Peter Gibbs, Jane E Visvader, Oliver M Sieber, Marco J Herold, Luca L Fava, Gemma L Kelly, Andreas Strasser
Loss-of-function but not gain-of-function properties of mutant TP53 are critical for the proliferation, survival and metastasis of a broad range of cancer cells. Cancer discovery (2023)
Allan Shuai Huang, Hui San Chin, Boris Reljic, Tirta M Djajawi, Iris K L Tan, Jia-Nan Gong, David Arthur Stroud, David Ching Siang Huang, Mark F van Delft, Grant Dewson
Mitochondrial E3 ubiquitin ligase MARCHF5 controls BAK apoptotic activity independently of BH3-only proteins. Cell death and differentiation (2022)
Annette V Jacobsen, Catia L Pierotti, Kym N Lowes, Amanda E Au, Ying Zhang, Nima Etemadi, Cheree Fitzgibbon, Wilhelmus J A Kersten, André L Samson, Mark F van Delft, David Ching Siang Huang, Hélène Jousset Sabroux, Guillaume L Lessene, John Silke, James G Murphy
The Lck inhibitor, AMG-47a, blocks necroptosis and implicates RIPK1 in signalling downstream of MLKL. Cell death & disease 13 (4) (2022)
Donia M Moujalled, Fiona C Brown, Chong Chyn Chua, Michael A Dengler, Giovanna Pomilio, Natasha S Anstee, Veronique Litalien, Ella R Thompson, Thomas David Morley, Sarah MacRaild, Ing Soo Tiong, Rhiannon Morris, Karen Dun, Adrian Carl Zordan, Jaynish S Shah, Sébastien Banquet, Ensar Halilovic, Erick J Morris, Marco J Herold, Guillaume L Lessene, Jerry M Adams, David Ching Siang Huang, Andrew W Roberts, Piers Blombery, Andrew H Wei
Acquired mutations in BAX confer resistance to BH3-mimetic therapy in Acute Myeloid Leukemia. Blood (2022)
Rachel Thijssen, Luyi Tian, Mary Ann Anderson, Christoffer Flensburg, Andrew Jarratt, Alexandra L Garnham, Jafar S Jabbari, Hongke Peng, Thomas E Lew, Charis E Teh, Quentin A Gouil, Angela Georgiou, Tania Tan, Tirta M Djajawi, Constantine S Tam, John Francis Seymour, Piers Blombery, Daniel H D Gray, Ian J Majewski, Matthew E Ritchie, Andrew W Roberts, David Ching Siang Huang
Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy. Blood 140 (20) (2022)
Charis E Teh, Hongke Peng, Meng-Xiao Luo, Tania Tan, Marie Trussart, Lauren J Howson, Chong Chyn Chua, Christine Muttiah, Fiona C Brown, Matthew E Ritchie, Andrew H Wei, Andrew W Roberts, Vanessa L Bryant, Mary Ann Anderson, Geoffrey J Lindeman, David Ching Siang Huang, Rachel Thijssen, Daniel H D Gray
Venetoclax treatment in cancer patients has limited impact on circulating T and NK cells. Blood advances (2022)
Sylvain Garciaz, Andrew A Guirguis, Sebastian Muller, Fiona C Brown, Yih-Chih Chan, Ali Motazedian, Caitlin L Rowe, James A Kuzich, Kah Lok Chan, Kevin Tran, Lorey Smith, Laura MacPherson, Brian J Liddicoat, Enid Y N Lam, Tatiana Cañeque, Marian L Burr, Veronique Litalien, Giovanna Pomilio, Mathilde Poplineau, Estelle Duprez, Sarah-Jane Dawson, Georg Ramm, Andrew Graham Cox, Kristin K Brown, David Ching Siang Huang, Andrew H Wei, Kate McArthur, Raphaël Rodriguez, Mark A Dawson
Pharmacological reduction of mitochondrial iron triggers a non-canonical BAX/BAK dependent cell death. Cancer discovery (2021)
Tsz-Yin Chan, Christina M Egbert, Julia E Maxson, Adam Siddiqui, Logan J Larsen, Kristina Kohler, Eranga Roshan Balasooriya, Katie L Pennington, Tsz-Ming Tsang, Madison Frey, Erik J Soderblom, Huimin Geng, Markus Müschen, Tetyana V Forostyan, Savannah Free, Gaelle Mercenne, Courtney J Banks, Jonard Corpuz Valdoz, Clifford J Whatcott, Jason M Foulks, David J Bearss, Thomas O'Hare, David Ching Siang Huang, Kenneth A Christensen, James D Moody, Steven L Warner, Jeffrey W Tyner, Joshua L Andersen
TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth. Nature communications 12 (1) (2021)
Thomas E Lew, Victor S Lin, Edward R Cliff, Piers Blombery, Ella R Thompson, Sasanka Mithila Handunnetti, David A Westerman, Bryone J Kuss, Constantine S Tam, David Ching Siang Huang, John Francis Seymour, Andrew W Roberts, Mary Ann Anderson
Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition. Blood advances 5 (20) (2021)
Tao Gui, Ming Liu, Bing Yao, Haiqin Jiang, Dongjun Yang, Qixiang Li, Xiangwei Zeng, Ying Wang, Jian Cao, Yexuan Deng, Xinyu Li, Peipei Xu, Liqin Zhou, Dake Li, Zhihui Wang, Ke Zen, David Ching Siang Huang, Bing Chen, Guiping Wan, Quan Zhao
TCF3 is epigenetically silenced by EZH2 and DNMT3B and functions as a tumor suppressor in endometrial cancer. Cell death and differentiation 28 (12) (2021)
Andrew W Roberts, Andrew H Wei, David Ching Siang Huang
BCL2 and MCL1 inhibitors for hematologic malignancies. Blood 138 (13) (2021)
Piers Blombery, Thomas E Lew, Michael A Dengler, Ella R Thompson, Victor S Lin, Xiangting Chen, Tamia Nguyen, Ashish Panigrahi, Sasanka Mithila Handunnetti, Dennis Carney, David A Westerman, Constantine S Tam, Jerry M Adams, Andrew H Wei, David Ching Siang Huang, John Francis Seymour, Andrew Roberts, Mary Ann Anderson
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL. Blood (2021)
Swee Heng Milon Pang, Joshua D'Rozario, Senora Mendonca, Tejasvini Bhuvan, Natalie L Payne, Di Zheng, Assifa Hisana, Georgia Wallis, Adele Barugahare, David R Powell, Jai Rautela, Nicholas D Huntington, Grant Dewson, David Ching Siang Huang, Daniel H D Gray, Tracy S P Heng
Mesenchymal stromal cell apoptosis is required for their therapeutic function. Nature communications 12 (1) (2021)
Rachel Thijssen, Sarah T Diepstraten, Donia Moujalled, Edward Chew, Christoffer Flensburg, Melissa X Shi, Michael A Dengler, Veronique Litalien, Sarah MacRaild, Maoshan Chen, Natasha S Anstee, Boris Reljić, Sarah S Gabriel, Tirta M Djajawi, Chris D Riffkin, Brandon J Aubrey, Catherine Chang, Lin Tai, Zhen Xu, Thomas Morley, Giovanna Pomilio, Claudia Bruedigam, Axel Kallies, David Arthur Stroud, Ashish Bajel, Ruth M Kluck, Steven W Lane, Marie Schoumacher, Sébastien Banquet, Ian J Majewski, Andreas Strasser, Andrew W Roberts, David Ching Siang Huang, Fiona C Brown, Gemma L Kelly, Andrew H Wei
Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias. Blood 137 (20) (2021)
Victor S Lin, Zhuo-Fan Xu, David Ching Siang Huang, Rachel Thijssen
BH3 Mimetics for the Treatment of B-Cell Malignancies-Insights and Lessons from the Clinic. Cancers 12 (11) (2020)
Tirta Mario Djajawi, Lei Liu, Jia-Nan Gong, Allan Shuai Huang, Ming-Jie Luo, Zhen Xu, Toru Okamoto, Melissa J Call, David Ching Siang Huang, Mark F van Delft
MARCH5 requires MTCH2 to coordinate proteasomal turnover of the MCL1:NOXA complex. Cell death and differentiation 27 (8) (2020)
Pasquale L Fedele, Yang Liao, Jia-Nan Gong, Yuan Yao, Mark F van Delft, Michael S Y Low, Lin Tai, Marco J Herold, Jacob T Jackson, Charis E Teh, Tania Tan, Lorraine A O'Reilly, Julie Tellier, George Grigoriadis, David Ching Siang Huang, Wei Shi, Stephen L Nutt, Simon N Willis
The transcription factor IRF4 represses proapoptotic BMF and BIM to licence multiple myeloma survival. Leukemia 35 (7) (2020)
Rachel Thijssen, Silvia Alvarez-Diaz, Clea Grace, Ming-Yuan Gao, David H Segal, Zhen Xu, Andreas Strasser, David Ching Siang Huang
Loss of RIPK3 does not impact MYC-driven lymphomagenesis or chemotherapeutic drug-induced killing of malignant lymphoma cells. Cell death and differentiation 27 (8) (2020)
Ming-Jie Luo, Michelle Palmieri, Chris D Riffkin, Anuratha Sakthianandeswaren, Tirta Mario Djajawi, Yumiko Hirokawa, Victoria Shuttleworth, David H Segal, Christine A White, Duong Nhu, Guillaume Lessene, Margaret Lee, Peter Gibbs, David Ching Siang Huang, Oliver M Sieber, Jia-Nan Gong
Defining the susceptibility of colorectal cancers to BH3-mimetic compounds. Cell death & disease 11 (9) (2020)
Charis E Teh, Jia-Nan Gong, David Segal, Tania Tan, Cassandra J Vandenberg, Pasquale L Fedele, Michael S Y Low, George Grigoriadis, Simon J Harrison, Andreas Strasser, Andrew W Roberts, David Ching Siang Huang, Garry P Nolan, Daniel H D Gray, Melissa E Ko
Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells. Cell death and differentiation 27 (7) (2020)
Sean P Brown, Brian Belmontes, Gordon Moody, Kathleen S Keegan, Danny Chui, Douglas A Whittington, David Ching Siang Huang, Leszek Poppe, Alan C Cheng, Mario Cardozo, Jonathan Houze, Yunxiao Li, Brian Lucas, Nick A Paras, Xianghong Wang, Joshua P Taygerly, Marc Vimolratana, Manuel Zancanella, Liusheng Zhu, Elaina Cajulis, Tao Osgood, Jan Sun, Leah J Damon, Regina K Egan, Patricia Greninger, Joseph D McClanaghan, Jianan Gong, Donia Moujalled, Giovanna Pomilio, Pedro Beltran, Cyril H Benes, Andrew W Roberts, Andrew Wei, Jude Canon, Angela Coxon, Paul E Hughes
AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies. Cancer discovery 8 (12) (2018)
Piers Blombery, Mary Ann Anderson, Jia-Nan Gong, Rachel Thijssen, Richard W Birkinshaw, Ella R Thompson, Charis E Teh, Tamia Nguyen, Zhen Xu, Christoffer Flensburg, Thomas E Lew, Ian J Majewski, Daniel H D Gray, David A Westerman, Constantine S Tam, John Francis Seymour, Peter E Czabotar, David Ching Siang Huang, Andrew W Roberts
Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. Cancer discovery 9 (3) (2018)
Delphine Merino, James R Whittle, François Vaillant, Antonin Serrano, Goknur Giner, Ana Leticia Maragno, Maïa Chanrion, Emilie Schneider, Bhupinder Pal, Xiang Li, Grant Dewson, Julius Gräsel, Kevin Liu, Najoua Lalaoui, David Segal, Marco J Herold, David Ching Siang Huang, Aaron T L Lun, Olivier Geneste, Guillaume L Lessene, Jane E Visvader, Geoffrey J Lindeman
Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer. Science translational medicine 9 (401) (2018)
Tatsuya Suzuki, Toru Okamoto, Hiroshi Katoh, Yukari Sugiyama, Shinji Kusakabe, Makoto Tokunaga, Junki Hirano, Yuka Miyata, Takasuke Fukuhara, Masahito Ikawa, Takashi Satoh, Sachiyo Yoshio, Ryosuke Suzuki, Masayuki Saijo, David Ching Siang Huang, Tatsuya Kanto, Shizuo Akira, Yoshiharu Matsuura
Infection with flaviviruses requires BCLXL for cell survival. PLoS pathogens 14 (9) (2018)
Antonin Serrano, Tiffany Khong, David Segal, Yuan Yao, Chris D Riffkin, Jean-Marc Garnier, Seong Lin Khaw, Guillaume L Lessene, Andrew Spencer, Marco J Herold, Andrew W Roberts, David Ching Siang Huang
Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1. Blood 128 (14) (2016)

David Ching Siang Huang.css-eqlu8i{font-size:small;padding-left:4px;} (David C S Huang, Xin Huang)

Publication Activity (10 Years)

Top Topics

Top Venues

David Ching Siang Huang (David C S Huang, Xin Huang)